<?xml version="1.0" encoding="UTF-8"?>
<p>Coronavirus disease 2019 (COVID-19), resulting from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has distressed medical services and economies worldwide and has had profound psychological effects since its emergence
 <xref rid="CIT0001" ref-type="bibr">
  <sup>1</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0002" ref-type="bibr">
  <sup>2</sup>
 </xref>. Among COVID-19 patients, about 81% have no or mild symptoms, with severe symptoms in 14% and critical illness in 5%
 <xref rid="CIT0002" ref-type="bibr">
  <sup>2</sup>
 </xref>. The clinical manifestations of SARS-CoV-2 infection often include, but are not limited to, fever, cough, fatigue, muscle soreness and abdominal pain, similar to severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV)
 <xref rid="CIT0002" ref-type="bibr">
  <sup>2</sup>
 </xref>. Risk factors for becoming critically ill with COVID-19 include cardiovascular disease, diabetes and obesity; however, healthy people of any age can become critically ill with COVID-19, although the current data suggest that individuals over 65â€‰years of age, particularly men, are more likely to have severe symptoms
 <xref rid="CIT0003" ref-type="bibr">
  <sup>3</sup>
 </xref>. Because SARS-CoV-2 infection has become a global pandemic, causing severe damage to public health
 <xref rid="CIT0004" ref-type="bibr">
  <sup>4</sup>
 </xref>, there is a desperate need for effective therapeutics.
</p>
